The Patent Finder

Antibodies That Target Human Protein Tyrosine Phosphatase-Beta (HPTP-BETA) and Methods of Use Thereof to Treat Ocular Conditions

Eyepoint, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 62/364,381, filed Jul 20, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,253,094Antibodies That Target Human Protein Tyrosine Phosphatase-Beta (HPTP-BETA) and Methods of Use Thereof to Treat Ocular Conditions
In force
 · High confidence
Eyepoint, Inc.In force
High confidence
US 10,597,452Methods of Treating Ocular Conditions by Administering Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-BETA)
In force
 · High confidence
Eyepoint, Inc.In force
High confidence
US 10,604,569Humanized Monoclonal Antibodies That Target Protein Tyrosine Phosphatase-Beta (Hptp-Beta / Ve-Ptp)
In force
 · High confidence
Eyepoint, Inc.In force
High confidence
US 11,136,389Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-BETA)
In force
 · High confidence
Eyepoint, Inc.In force
High confidence
US 11,180,551Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-Beta)
In force
 · High confidence
Eyepoint, Inc.In force
High confidence
US 12,145,986A Method of Treating an Ocular Condition by Administering a Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-Beta)
In force
 · Medium confidence
Eyepoint, Inc.In force
Medium confidence
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited